Significant developments originating from
Hologic Inc. (HOLX) have been noted and analyzed. Holding a promising long-term position, HOLX has been highlighted for its commitments to report at various global healthcare conferences. With a robust balance sheet,
Candriam S.C.A maintains a notable $99.76 Million stock holding in HOLX. Amidst fluctuating short interests, there's been an increase in Wall Street interest, particularly now that HOLX is not flying under the radar. Although the stock has slightly dipped, Zacks Research analysts remain confident in HOLX's Q3 2025 Earnings due to recent Earnings Surpass Estimates and a rise in Margins. Reports also detail a revised 2024 outlook that now tops estimates, while still underperforming market expectations. HOLX's Q3 2024 Earnings projects revenue surpassing estimates, with key figures such as
EPS of $0.82 and Revenue of $1.01 Billion. Despite revenue targets not being met, Q3 earnings beat expectations. Caution, however, is advised around a classified 'most serious' recall on HOLX's implants by the FDA. In other moves, HOLX has acquired
Endomagnetics Ltd, a Breast Surgical Guidance Company, and announced potential facility closures in their diagnostics division, indicating significant strategic movement. New board directors have been elected, C-level executives have sold shares, and street analysts remain largely bullish on HOLX's future.
Hologic HOLX News Analytics from Fri, 28 Sep 2012 07:00:00 GMT to Sat, 07 Sep 2024 14:17:25 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 4
